ABI
INVA icon

Adamant Biomedical Investments’s Innoviva INVA Stock Holding History

Adamant Biomedical Investments’s Portfolio INVA Stock Details INVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$495K Sell
35,000
-65,000
-65% -$977K 0.12% 92
2014
Q3 		$1.71M Buy
+100,000
New +$2.3M 0.43% 66

Other funds holding INVA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
PC
Perry Capital New York $334M AUM 8.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LM
Litespeed Management New York $48.2M AUM 9.81% 1-Year Est. Return

Adamant Biomedical Investments's INVA Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its Innoviva (INVA) stake by 65% in Q4 2014, selling an estimated $977K and leaving 35,000 shares worth $495K. The position accounts for 0.12% of the portfolio, ranked #92.

Adamant Biomedical Investments first reported a position in INVA in Q3 2014 and has held it in 2 quarters since. The position peaked at $1.71M in Q3 2014. 114 funds tracked by Wall St. Rank hold INVA as of Q4 2014.

  • Adamant Biomedical Investments held 35,000 shares of Innoviva worth $495K as of Q4 2014.
  • Adamant Biomedical Investments sold 65,000 Innoviva shares in Q4 2014, an estimated $977K.
  • Innoviva made up 0.12% of Adamant Biomedical Investments's portfolio in Q4 2014, its #92 holding.
  • Adamant Biomedical Investments first reported a position in Innoviva in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's Innoviva position peaked at $1.71M in Q3 2014.
  • 114 funds tracked by Wall St. Rank held Innoviva as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.